Evidence map›Paper›PMID 32676425›Full record

ReviewTranslational andrology and urology2020

Role of application of tadalafil 5 mg once-daily (≥6 months) in men with erectile dysfunction from six randomized controlled trials.

Jiajia Ma, Zi Liu, Jitao Wu, Zhongbao Zhou, Xuebao Zhang, Yuanshan Cui, Chunhua Lin

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational andrology and urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jiajia MaDepartment of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Zi LiuDepartment of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Jitao WuDepartment of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Zhongbao ZhouDepartment of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Xuebao ZhangDepartment of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Yuanshan CuiDepartment of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Chunhua LinDepartment of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Yuhuangding Hospital · CNQingdao University · CNBinzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This meta-analysis was performed to assess the efficacy and safety of taking tadalafil 5 mg once-daily for at least 6 months in the treatment of erectile dysfunction (ED). Based on databases: MEDLINE, EMBASE and Cochrane Controlled Trials Register, this analysis was performed to collect randomized controlled trials (RCTs) of tadalafil 5mg once-daily in treating ED over 6 months. Reviewers also investigated the references of each literature. The meta-analysis covered a total of 1,596 patients in six RCTs. The tadalafil group performed a better effect in terms of the international index of erectile function-erectile function (IIEF) domain (P=0.005) for the treatment of ED compared with the placebo group. Safety assessments including discontinuations due to adverse events (AEs) (P=0.31) and treatment-emergent AEs (P=0.06) indicated that the tadalafil group had a better tolerate. The analysis elucidates that the dose of 5 mg per day of tadalafil showed a good effect after the treatment of at least 6 months relative to the control group with fewer side effects.

Indexed as

erectile dysfunction (ED)once-dailyRandomized controlled trialTadalafil

Identifiers

PMID32676425
PMCPMC7354289
OpenAlexW3035008404

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.